מדינה: אוסטרליה
שפה: אנגלית
מקור: Department of Health (Therapeutic Goods Administration)
Cisatracurium besylate
Hospira Pty Limited
Medicine Registered
________________________________________________________________________________ DBL™ Cisatracurium Injection Concentrate 1 DBL™ CISATRACURIUM INJECTION CONCENTRATE _ _ _Cisatracurium besylate (sis-at-rah-CURE-e-um BESS-ee-late) _ CONSUMER MEDICINE INFORMATION _Date of Dispensing_ _Consumer _ _Name _ _ Pharmacist _ _Name _ _Consumer _ _Address _ _ Pharmacist _ _Address _ _Consumer _ _Address _ _ Pharmacist _ _Address _ WHAT IS IN THIS LEAFLET This leaflet answers some common questions about DBL™ Cisatracurium Injection Concentrate (cisatracurium besylate). It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you being given this medicine against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT BEING GIVEN THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT DBL™ CISATRACURIUM INJECTION CONCENTRATE IS USED FOR This medicine is used to relax the body’s muscles during surgery or other medical procedures. The medicine contains cisatracurium besylate, which belongs to a family of medicines called neuromuscular blockers. The medicine works by blocking the effects of one of the body’s chemical messengers called acetylcholine. Acetycholine is involved in muscle contraction. By relaxing your body’s muscles cisatracurium besylate makes it easier for you to be kept asleep (under anaesthesia) or sedation. Cisatracurium besylate is only used in conjunction with an anaesthetic, so you will be asleep during the procedure. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY THIS MEDICINE HAS BEEN PRESCRIBED FOR קרא את המסמך השלם
Product Information - Australia Version 1.0 - 1 - DBL TM CISATRACURIUM INJECTION CONCENTRATE NAME OF MEDICINE Cisatracurium besylate DESCRIPTION The active ingredient, Cisatracurium besylate, is a white to off-white or yellowish powder. DBL TM Cisatracurium Injection Concentrate is presented as a clear, colourless or faint yellow solution containing cisatracurium besylate, benzenesulfonic acid and water for injections, pH is 3.0 – 3.7. It contains no antimicrobial preservative. DBL TM Cisatracurium Injection Concentrate is available in the following presentations: Cisatracurium (as besylate salt), 5 mg per 2.5 mL Cisatracurium (as besylate salt), 10 mg per 5 mL Chemical name: (1R,1’R,2R,2’R)-2,2’- (3,11-dioxo-4, 10-dioxatridecamethylene)-_bis_- (1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-veratry-lisoquinolinium) dibenzenesulfonate. Molecular formula: C 65 H 82 N 2 O 18 S 2 Molecular weight: 1,243.5 CAS number: 96946-42-8 Product Information - Australia Version 1.0 - 2 - The structural formula of cisatracurium besylate is shown below:- ACTIONS Cisatracurium besylate, a stereoisomer of atracurium, is an intermediate duration, nondepolarising benzylisoquinolinium skeletal muscle relaxant. PHARMACOLOGY PHARMACODYNAMICS Cisatracurium besylate binds to cholinergic receptions on the motor endplate to antagonise the action of acetylcholine, resulting in a competitive block of neuromuscular transmission. This action is readily reversed by anticholinesterase agents such as neostigmine. The ED 95 (dose required to produce 95% depression of the twitch response of the adductor pollicis muscle to stimulation of the ulnar nerve) of cisatracurium besylate is estimated to be 0.05 mg/kg bodyweight during opioid anaesthesia (thiopentone, fentanyl, midazolam). The recommended intubation dose for cisatracurium besy קרא את המסמך השלם